ICD-11 code 2C73.2 refers to granulosa cell malignant tumor of the ovary, a rare type of ovarian cancer that originates in the granulosa cells of the ovaries. These tumors are classified as malignant due to their tendency to grow and spread to other parts of the body. Granulosa cell tumors can be divided into two subtypes: adult and juvenile, with the adult type being more common in women over the age of 50.
Granulosa cell malignant tumors of the ovary are often associated with hormonal imbalances, leading to symptoms such as abnormal vaginal bleeding, abdominal pain, and changes in menstrual cycles. These tumors may also produce estrogen, resulting in symptoms like breast tenderness, bloating, and weight gain. Diagnosis of granulosa cell malignant tumors typically involves imaging studies such as ultrasound or MRI, as well as biopsy to confirm the presence of cancerous cells.
Treatment for granulosa cell malignant tumors may involve surgery to remove the tumor and affected tissue, as well as chemotherapy or radiation therapy to kill any remaining cancer cells. Prognosis for patients with granulosa cell malignant tumors can vary depending on the stage of the cancer at diagnosis, with early detection leading to better outcomes. Regular follow-up appointments and monitoring are crucial for patients with these tumors to detect any recurrence or metastasis.
Table of Contents:
- #️⃣ Coding Considerations
- 🔎 Symptoms
- 🩺 Diagnosis
- 💊 Treatment & Recovery
- 🌎 Prevalence & Risk
- 😷 Prevention
- 🦠 Similar Diseases
#️⃣ Coding Considerations
The SNOMED CT code equivalent to the ICD-11 code 2C73.2, which represents Granulosa cell malignant tumor of the ovary, is 363406005. SNOMED CT, which stands for Systematized Nomenclature of Medicine Clinical Terms, is a comprehensive and multilingual clinical terminology that provides a standardized way to represent health information across different healthcare systems.
This specific SNOMED CT code is used to uniquely identify and classify Granulosa cell malignant tumors of the ovary in healthcare databases and electronic health records. It allows for precise and consistent coding of this specific type of cancer, enabling healthcare professionals to accurately document patient diagnoses, treatments, and outcomes.
By using standardized codes like the SNOMED CT code 363406005 for Granulosa cell malignant tumor of the ovary, healthcare organizations can improve data interoperability, facilitate research, and enhance patient care by ensuring that relevant information is easily accessible and shareable among different healthcare providers.
In the United States, ICD-11 is not yet in use. The U.S. is currently using ICD-10-CM (Clinical Modification), which has been adapted from the WHO’s ICD-10 to better suit the American healthcare system’s requirements for billing and clinical purposes. The Centers for Medicare and Medicaid Services (CMS) have not yet set a specific date for the transition to ICD-11.
The situation in Europe varies by country. Some European nations are considering the adoption of ICD-11 or are in various stages of planning and pilot studies. However, as with the U.S., full implementation may take several years due to similar requirements for system updates and training.
🔎 Symptoms
Symptoms of 2C73.2, or Granulosa cell malignant tumor of the ovary, may vary depending on the size and location of the tumor. Many patients with this condition may experience abdominal pain or discomfort, bloating, and an increased abdominal girth due to the tumor’s growth within the pelvis.
Women with granulosa cell malignant tumor of the ovary may also present with abnormal vaginal bleeding, such as postmenopausal bleeding or irregular menstrual periods. Some patients may notice changes in their menstrual cycle, including heavier or longer periods than usual. In more advanced cases, individuals may develop symptoms of metastasis, such as shortness of breath, weight loss, and fatigue.
Other possible symptoms of this condition can include pelvic pressure or fullness, frequent urination, or constipation. As the tumor grows, it may exert pressure on nearby organs and structures, leading to a range of gastrointestinal and genitourinary symptoms. In some cases, individuals with granulosa cell malignant tumor of the ovary may also develop ascites, a buildup of fluid in the abdominal cavity, causing increased abdominal distension and discomfort.
🩺 Diagnosis
Diagnosis of 2C73.2, granulosa cell malignant tumor of the ovary, typically involves a combination of imaging studies and laboratory tests. Imaging studies such as ultrasound, CT scans, or MRI can help visualize the size and location of the tumor within the ovary. These imaging studies can also provide valuable information on whether the tumor has spread to other areas of the body.
In addition to imaging studies, blood tests may be conducted to measure levels of certain biomarkers that are associated with ovarian cancer, such as CA-125. Elevated levels of these biomarkers can indicate the presence of a malignant tumor. However, it is important to note that these biomarkers are not specific to 2C73.2 and can also be elevated in other types of ovarian cancer.
The definitive diagnosis of 2C73.2 is typically made through a biopsy of the ovarian tumor. During a biopsy, a small sample of tissue is collected from the tumor and examined under a microscope by a pathologist. This allows for the determination of the specific type of tumor, such as granulosa cell tumor, as well as the presence of malignant cells. The biopsy results will also provide crucial information on the tumor’s grade and stage, which are important factors in determining prognosis and treatment options.
💊 Treatment & Recovery
Treatment for 2C73.2, also known as granulosa cell malignant tumor of the ovary, typically involves a combination of surgery, chemotherapy, and sometimes radiation therapy. The primary treatment is surgical removal of the tumor, which may include removing the affected ovary as well as surrounding tissue.
Following surgery, chemotherapy is often recommended to target any remaining cancer cells and reduce the risk of recurrence. Chemotherapy drugs may be administered orally or intravenously, depending on the specific treatment plan. In some cases, radiation therapy may also be used to destroy any remaining cancer cells in the area.
Recovery from treatment for 2C73.2 can vary depending on the stage and aggressiveness of the cancer, as well as the overall health of the patient. Side effects of treatment may include fatigue, nausea, hair loss, and changes in appetite. It is important for patients to follow up with their healthcare team regularly to monitor their recovery progress and address any ongoing side effects or concerns. Supportive care, such as nutritional counseling and emotional support, may also be recommended to help patients manage the physical and emotional challenges of treatment and recovery.
🌎 Prevalence & Risk
The prevalence of 2C73.2, Granulosa cell malignant tumor of the ovary, varies across different regions of the world. In the United States, granulosa cell tumors account for approximately 2-5% of all ovarian malignancies. Although considered rare, they are the most common type of sex cord-stromal tumors in this region. The incidence of granulosa cell tumors in the United States has been reported to be around 0.4 cases per 100,000 women per year.
In Europe, the prevalence of granulosa cell malignant tumors of the ovary is slightly higher compared to the United States. Studies have shown that these tumors account for around 5-10% of all ovarian malignancies in certain European countries. The incidence rate in Europe is estimated to be around 0.6-1.2 cases per 100,000 women per year. However, it is important to note that prevalence rates may vary among different European regions.
In Asia, the prevalence of granulosa cell malignant tumors of the ovary is relatively lower compared to the United States and Europe. These tumors account for approximately 1-3% of all ovarian malignancies in certain Asian countries. The incidence rate in Asia is reported to be around 0.2-0.6 cases per 100,000 women per year. It is worth noting that there may be underreporting of cases in some Asian regions due to limited access to healthcare facilities.
In Africa, data on the prevalence of 2C73.2, Granulosa cell malignant tumor of the ovary, is limited. However, studies suggest that these tumors are rare in this region and account for a small proportion of all ovarian malignancies. The incidence rate in Africa is estimated to be lower than that of the United States, Europe, and Asia. Further research and data collection are needed to better understand the prevalence of granulosa cell tumors in Africa.
😷 Prevention
To prevent Granulosa cell malignant tumour of ovary (2C73.2), regular gynecological screenings are essential. These screenings may include pelvic exams, transvaginal ultrasounds, and blood tests to monitor hormone levels. Early detection of any abnormalities in the ovaries can lead to prompt treatment and a better prognosis.
Maintaining a healthy lifestyle can also help prevent Granulosa cell malignant tumour of ovary. This includes eating a balanced diet rich in fruits, vegetables, and whole grains, as well as engaging in regular physical activity. Obesity has been linked to an increased risk of developing certain types of ovarian cancer, so maintaining a healthy weight is important.
Limiting exposure to certain risk factors can also help prevent Granulosa cell malignant tumour of ovary. These risk factors may include smoking, certain fertility drugs, and hormone replacement therapy. Avoiding these known risk factors can help reduce the likelihood of developing this type of ovarian cancer.
🦠 Similar Diseases
Granulosa cell tumors of the ovary are a rare type of ovarian cancer that can be classified based on their behavior and pathology. One similar disease is adult granulosa cell tumor, coded as 2C73.0, which is the most common type of granulosa cell tumor. These tumors typically have a better prognosis compared to other ovarian cancers.
Another related disease is juvenile granulosa cell tumor, coded as 2C73.1, which occurs in younger individuals, often children or adolescents. This type of tumor is distinct from the adult form and tends to have a more aggressive course. Juvenile granulosa cell tumors are typically treated with surgery and sometimes additional therapies such as chemotherapy.
A third related disease is thecomatous tumors of the ovary, coded as 2C73.3, which are also rare ovarian neoplasms composed of granulosa and thecal cells. These tumors can be difficult to distinguish from granulosa cell tumors histologically and may have similar clinical presentations. Thecomatous tumors may occur in conjunction with other ovarian neoplasms or syndromes such as McCune-Albright syndrome.